EBITDA: Income before interest, taxes, depreciation and amortization.
Viridian Therapeutics, Inc. (VRDN) had EBITDA of $-90.56M for the most recently reported fiscal quarter, ending 2024-12-31.
| Income Statement Financials | |
$0.07M |
|
$-79.72M |
|
-- |
|
$0.07M |
|
$87.54M |
|
$-87.47M |
|
$7.75M |
|
$-79.72M |
|
$-79.72M |
|
$-79.72M |
|
$-79.72M |
|
$-79.72M |
|
$-79.72M |
|
$-87.47M |
|
|
EBITDA |
$-90.56M |
67.89M |
|
67.89M |
|
$-0.11 |
|
$-0.11 |
|
| Balance Sheet Financials | |
$738.46M |
|
$1.24M |
|
$3.94M |
|
$742.40M |
|
$47.87M |
|
$20.58M |
|
$22.89M |
|
$70.76M |
|
$482.75M |
|
$671.64M |
|
$671.64M |
|
80.99M |
|
| Cash Flow Statement Financials | |
$-232.32M |
|
$-228.65M |
|
$457.74M |
|
$102.83M |
|
$99.59M |
|
$-3.23M |
|
$42.15M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
15.43 |
|
-- |
|
-- |
|
0.03 |
|
0.03 |
|
100.00% |
|
-121487.50% |
|
-121487.50% |
|
-- |
|
-110729.20% |
|
-110729.20% |
|
$-232.83M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-16.51% |
|
-11.87% |
|
-10.74% |
|
-11.52% |
|
$8.29 |
|
$-3.43 |
|
$-3.42 |
|